HomeCompareEPIX vs EQR

EPIX vs EQR: Dividend Comparison 2026

EPIX yields 840.47% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPIX wins by $4215412.23M in total portfolio value
10 years
EPIX
EPIX
● Live price
840.47%
Share price
$0.20
Annual div
$1.69
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4215412.28M
Annual income
$3,415,908,279,597.25
Full EPIX calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — EPIX vs EQR

📍 EPIX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEPIXEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EPIX + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EPIX pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPIX
Annual income on $10K today (after 15% tax)
$71,440.13/yr
After 10yr DRIP, annual income (after tax)
$2,903,522,037,657.66/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EPIX beats the other by $2,903,522,033,003.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPIX + EQR for your $10,000?

EPIX: 50%EQR: 50%
100% EQR50/50100% EPIX
Portfolio after 10yr
$2107706.16M
Annual income
$1,707,954,142,536.42/yr
Blended yield
81.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

EPIX
Analyst Ratings
2
Buy
3
Hold
Consensus: Hold
Price Target
$9.50
+4621.7% upside vs current
Range: $2.00 — $17.00
Altman Z
1.1
Piotroski
3/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPIX buys
0
EQR buys
0
No recent congressional trades found for EPIX or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEPIXEQR
Forward yield840.47%5.87%
Annual dividend / share$1.69$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$4215412.28M$47.8K
Annual income after 10y$3,415,908,279,597.25$5,475.61
Total dividends collected$4152700.41M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold
Analyst price target$9.50$70.35

Year-by-year: EPIX vs EQR ($10,000, DRIP)

YearEPIX PortfolioEPIX Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$94,747$84,047.22$11,380$679.82+$83.4KEPIX
2$845,608$744,228.02$13,014$837.25+$832.6KEPIX
3$7,112,413$6,207,612.95$14,961$1,036.20+$7.10MEPIX
4$56,406,815$48,796,533.54$17,297$1,289.22+$56.39MEPIX
5$422,031,389$361,676,096.60$20,121$1,613.15+$422.01MEPIX
6$2,980,575,750$2,529,002,163.86$23,561$2,030.84+$2980.55MEPIX
7$19,881,694,862$16,692,478,809.61$27,783$2,573.54+$19881.67MEPIX
8$125,334,964,899$104,061,551,396.31$33,013$3,284.39+$125334.93MEPIX
9$747,200,001,618$613,091,589,175.98$39,547$4,223.51+$747199.96MEPIX
10$4,215,412,281,328$3,415,908,279,597.25$47,791$5,475.61+$4215412.23MEPIX

EPIX vs EQR: Complete Analysis 2026

EPIXStock

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Full EPIX Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this EPIX vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPIX vs SCHDEPIX vs JEPIEPIX vs OEPIX vs KOEPIX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.